Edwards plans tax-free spin-off of Critical Care, issues 2024 sales guidance $6.3-6.6B

Edwards Lifesciences Corp

Edwards plans tax-free spin-off of Critical Care at end of 2024; Katie Szyman to be CEO of new company.
2024 guidance: sales $6.3-6.6B (8-10% constant currency growth), adjusted EPS $2.70-2.80.
2024 TAVR sales $4.0-4.3B (8-10% growth); TMTT sales $280-320M.
Board authorized $1B additional share repurchase authorization.
Clinical milestones: PROGRESS enrollment complete early 2024, EARLY TAVR data at TCT 2024, EVOQUE US approval mid-2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.